![](/img/cover-not-exists.png)
A phase 2 study of ofatumumab (Arzerra ® ) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL)*
Chen, Christine I., Paul, Harminder, Le, Lisa W., Wei, Ellen N., Snitzler, Susi, Wang, Trina, Levina, Olga, Kakar, Sumeet, Lau, Anthea, Queau, Michelle, Johnston, James B., Smith, Deborah A., Trudel,Language:
english
Journal:
Leukemia & Lymphoma
DOI:
10.1080/10428194.2018.1468892
Date:
June, 2018
File:
PDF, 1.09 MB
english, 2018